A patient with depression says she was "stuck" until AbbVie's Vraylar gave her "a lift," which is the theme of the company's latest ad campaign for the mental health drug. Vraylar, a sales blockbuster ...

Allergan depicts the ups and downs of bipolar disorder with an elevator metaphor in its newest Vraylar ad campaign. The campaign comes on the heels of the antipsychotic drug’s expanded approval for ...

AbbVie ABBV announced that the FDA has approved Vraylar (cariprazine) for the adjunctive treatment of patients with major depressive disorder (MDD). Vraylar is presently approved for treating ...

This listing is a new step towards more equitable access to mental illness medication in Canada. As up to 90% of Canadians with serious mental illness are unemployed 3, public plan coverage is ...

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include adjunctive therapy for major depressive disorder, part of a plan to build sales of the drug to peak ...

AbbVie's longstanding alliance with Hungarian drugmaker Gedeon Richter has already given it one blockbuster medicine – Vraylar for schizophrenia and bipolar disorder – and the two partners have just ...

Vraylar (cariprazine) is a powerful antipsychotic medication that is approved by the Food and Drug Administration (FDA) to treat schizophrenia, bipolar disorder, and major depressive disorder (MDD).

The approval of medicines called second-generation antipsychotics has allowed bipolar I and other associated conditions to be treated. A person with bipolar I disorder can go through various mood ...